About Revenio Group
Revenio Group is a publicly listed company based in Vantaa (Finland) founded in 2001. Diagnostic devices for medical applications are developed and commercialized. The company has 241 employees. Revenio Group has completed 5 acquisitions, including CenterVue, Oscare Medical and Thirona. Revenio Group offers products and services including iCare Tonometry Devices, iCare Eye Fundus Imaging Devices, iCare Perimeters, and iCare Clinical Software. Its focus areas include Diversified Diagnostics. Its legal entity is Revenio Group Oyj.
Company details
Revenio Group was founded in 2001 and is based in Vantaa, Finland. Operations focus on the medical diagnostics sector, where handheld devices are developed and commercialized. Subsidiaries include Oscare Medical, which produces ultrasound tools for osteoporosis and osteopenia detection, and Icare Finland, which manufactures tonometers for intraocular pressure measurement at point-of-care. A dedicated research unit is advancing a device for skin cancer identification.
- Headquarters Vantaa, Finland
- Employees 241
- Stage Public
- SectorsHealthcare
- Website reveniogroup.fi/fi
- Social LinkedIn X
- Legal Name Revenio Group Oyj
- Annual Revenue$128.87 M (USD)5.95as on Dec 31, 2025
- Net Profit$20.46 M (USD)-5.87as on Dec 31, 2025
- EBITDA$34.86 M (USD)-0.73as on Dec 31, 2025
- Latest Funding Round$47.52M (USD), Post-IPO
Apr 2019
- Employee Count241
- Investments & AcquisitionsCenterVue
& 4 more
Products & Services of Revenio Group
Revenio Group offers a comprehensive portfolio of products and services, including iCare Tonometry Devices, iCare Eye Fundus Imaging Devices, iCare Perimeters, and iCare Clinical Software.
Devices for accurate measurement of eye pressure.
Tools for capturing images of the eye fundus.
Devices for visual field testing in eye examinations.
Software for managing and analyzing eye diagnostic data.
Funding Insights of Revenio Group
- Total Rounds 1
- Last Round Post-IPO — $47.52M
- First Round $47.52M
(Apr 2019)
All 1 funding rounds of Revenio Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $47.52M | Post-IPO | – | – | – |
People of Revenio Group
8 people are tracked at Revenio Group (4 in leadership, 4 in team); the tracked headcount is 241.
| Name | Role | Group |
|---|---|---|
Robin Pulkkinen | CFO | Leadership |
Heli Huopaniemi | Vice President of Quality | Leadership |
Jouni Toijala | Chief Executive Officer | Leadership |
Hanna Vuornos | VP, People & Culture | Leadership |
Silja Liuska | Business Controller | Team |
Paula Meriluoto | Group Controller | Team |
Riikka Vartiainen | Conversation Specialist & Communication Confidence Coach | Team |
Malviina Kettunen | Financial Controller | Team |
Complete people profiles for Revenio Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Revenio Group
Revenio Group is a publicly listed company on the OMXHEX with ticker symbol REG1V in Finland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Oct 2001
- Listed onNASDAQ OMX: REG1V
- Listed entityRevenio Group Oyj
- Exchange sectorHealth technology
- ISINFI0009010912
- Share price11.46 EUR (+0.88% on the day) · 2026-10-14
- Market capitalisation477,518,321.00 EUR
- Price to earnings27.7
- EPS (diluted, trailing year)0.41 EUR
- Dividend yield2.99%
- Volume (last session)23,971
Financials of Revenio Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 109.7M EUR | 17.4M EUR | 29.7M EUR |
| 2024 | 103.5M EUR | 18.5M EUR | 29.9M EUR |
| 2023 | 96.6M EUR | 19.1M EUR | 30.1M EUR |
| 2022 | 97.0M EUR | 21.8M EUR | 32.9M EUR |
| 2021 | 78.8M EUR | 17.3M EUR | 25.6M EUR |
Detailed financial statements for Revenio Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Revenio Group
Revenio Group has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include CenterVue, Oscare Medical and Thirona.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of diagnostic, screening, and lens finishing equipment for eye care | visionix.com | Jerusalem, Israel | 1993 | Apr 2026 | •••• | |
AI-based medical image analysis software is provided for diagnostics. | thirona.eu | Nijmegen, Netherlands | 2014 | Aug 2024 | •••• | |
A platform for secure clinical data sharing is offered by iCare OCULO. | oculo.com.au | Melbourne, Australia | 2015 | Mar 2021 | •••• | |
Fundus imaging devices are developed for ophthalmological diagnostics. | centervue.com | Padua, Italy | 2008 | Apr 2019 | $65.87M | |
Ultrasound devices for bone strength screening are developed. | oscaremedical.com | Vantaa, Finland | 2007 | Dec 2013 | •••• |
Complete acquisition details for Revenio Group
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Revenio Group
8 dated milestones of Revenio Group across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Revenio Group is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Oscare Medical.
- Acquisition Acquires CenterVue.
- Funding First funding round of $47.5M.
- Acquisition Acquires iCare OCULO.
- Acquisition Acquires Thirona.
- Acquisition Acquires Visionix.
Web traffic of Revenio Group
The website of Revenio Group (reveniogroup.fi) receives about 2.1K visits a month.
- Monthly visits2.1K
▼ 8.6% vs previous month
Websites whose visitors overlap most with Revenio Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
qfx.quartalflife.com | qfx.quartalflife.com | 100% | – | ||
| kauppalehti.fi | 100% | 7.9M | #9,536 | View details | |
news.cision.com | news.cision.com | 60% | #183,866 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Revenio Group
Complete news archive for Revenio Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Revenio Group
Revenio Group was founded in 2001 and raised its 1st funding round 18 years after it was founded.
Revenio Group is headquartered in Vantaa, Finland.
Revenio Group has 241 employees.
Annual revenue of Revenio Group is $128.87M as on Dec 31, 2025.
Revenio Group was founded in 2001 and is based in Vantaa, Finland. Operations focus on the medical diagnostics sector, where handheld devices are developed and commercialized. Subsidiaries include Oscare Medical, which produces ultrasound tools for osteoporosis and osteopenia detection, and Icare Finland, which manufactures tonometers for intraocular pressure measurement at point-of-care. A dedicated research unit is advancing a device for skin cancer identification.
Revenio Group offers iCare Tonometry Devices, iCare Eye Fundus Imaging Devices, iCare Perimeters, and iCare Clinical Software.
Yes, Revenio Group is publicly traded on OMXHEX under the ticker symbol REG1V.
Revenio Group has made 5 acquisitions, including CenterVue, Oscare Medical, and Thirona.
Revenio Group operates through Revenio Group Oyj.